Mark Taylor

Mark Taylor co-founded Hallux and has served as the company’s CEO since its formation in 2012.

Mr. Taylor has over 30 years in the specialty pharmaceutical and dermatology sectors serving as a senior executive of several public companies, a healthcare investment banker, and a sell-side pharmaceutical analyst.

Prior to starting Hallux, Mr. Taylor was Senior Vice President of Corporate Development for Obagi Medical Products Inc., the market share leader in the dermatology physician dispensed products channel. Valeant Pharmaceuticals International (now Bausch Health Companies Inc.) acquired Obagi in April 2013.

Mr. Taylor also worked at Roth Capital Partners, LLC, where he was the firm’s pharmaceutical analyst. Mr. Taylor coverered as many as 20 specialty drug companies at a time and was named to the prestigious Forbes and Wall Street Journal “Best on the Street” analyst ranking multiple times.

Prior to his work as a drug analyst, Mr. Taylor ran the largest division at ICN Pharmaceuticals Inc. (now Bausch Health) as Executive Vice President, North America. Under Mr. Taylor’s leadership, ICN expanded its dermatology division in the United States and Canada by adding prescription products, physician dispensed cosmeceuticals, and light activated devices to its portfolio.

Mr. Taylor also served as Vice President of Business Development at Watson Pharmaceuticals (now Allergan plc.), another branded products provider with an emphasis at the time in branded dermatology.

Mark is a graduate of Tulane University and served on the board of Medical Care Corporation, a company focused on Alzheimer’s research and diagnosis. In 2019, Mr. Taylor authored his first book entitled “Warrior CEO” a glossy, pictorial accounting of the near 4-decade quest of Milan Panic and his ICN Pharmaceuticals team to bring to market the blockbuster antiviral ribavirin.